{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:20:19Z","timestamp":1767032419068,"version":"3.48.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Industry-university Research Practice Project (2023) and Shanghai Jiao Tong University \u201cJiaotong Star\u201d Plan Medical Engineering Cross Research Project","award":["(20230103, YG2021QN07)"],"award-info":[{"award-number":["(20230103, YG2021QN07)"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81972655"],"award-info":[{"award-number":["No. 81972655"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04434-5","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:36:14Z","timestamp":1763717774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive assessment beyond eosinophils in eosinophilic esophagitis: an updated network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yangbao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"4434_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF01296781","volume":"38","author":"SE Attwood","year":"1993","unstructured":"Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38:109\u201316.","journal-title":"Dig Dis Sci"},{"key":"4434_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/tgh-22-15","volume":"8","author":"SS Rabinowitz","year":"2023","unstructured":"Rabinowitz SS, Yu L, Geraghty P. Eoe behaves as a unique Th2 disease: a narrative review. Transl Gastroenterol Hepatol. 2023;8:11.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"2","key":"4434_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","volume":"154","author":"ES Dellon","year":"2018","unstructured":"Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319-332.e3.","journal-title":"Gastroenterology"},{"issue":"20","key":"4434_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells12202473","volume":"12","author":"S Massironi","year":"2023","unstructured":"Massironi S, Mulinacci G, Gallo C, et al. Mechanistic insights into eosinophilic esophagitis: therapies targeting pathophysiological mechanisms. Cells. 2023;12(20):2473.","journal-title":"Cells"},{"issue":"1","key":"4434_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2022.03.025","volume":"163","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Khoury P, Muir AB, et al. A clinical severity index for eosinophilic esophagitis: development, consensus, and future directions. Gastroenterology. 2022;163(1):59\u201376.","journal-title":"Gastroenterology"},{"key":"4434_CR6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","volume":"390","author":"ME Rothenberg","year":"2024","unstructured":"Rothenberg ME, Dellon ES, Collins MH, et al. Eosinophil depletion with benralizumab for eosinophilic esophagitis. N Engl J Med. 2024;390:2252\u201363.","journal-title":"N Engl J Med"},{"key":"4434_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178\u201389.","journal-title":"J Clin Epidemiol"},{"key":"4434_CR8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"4434_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","volume":"19","author":"A B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau A, Boyne DJ, Slater J, et al. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med Res Methodol. 2019;19:196.","journal-title":"BMC Med Res Methodol"},{"key":"4434_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","volume":"152","author":"ES Dellon","year":"2017","unstructured":"Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152:776\u201386.","journal-title":"Gastroenterology"},{"key":"4434_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","volume":"157","author":"AJ Lucendo","year":"2019","unstructured":"Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157:74-86.e15.","journal-title":"Gastroenterology"},{"issue":"3","key":"4434_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","volume":"20","author":"I Hirano","year":"2022","unstructured":"Hirano I, Collins MH, Katzka DA, et al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3):525-534.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"4434_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","volume":"158","author":"I Hirano","year":"2020","unstructured":"Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111-122.e10.","journal-title":"Gastroenterology"},{"key":"4434_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","volume":"156","author":"I Hirano","year":"2019","unstructured":"Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156:592-603.e10.","journal-title":"Gastroenterology"},{"key":"4434_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","volume":"129","author":"JM Spergel","year":"2012","unstructured":"Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456-463.e3.","journal-title":"J Allergy Clin Immunol"},{"key":"4434_CR16","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","volume":"117","author":"E Dellon","year":"2022","unstructured":"Dellon E, Chehade M, Genta RM, et al. S446\u2003results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE. Am J Gastroenterol. 2022;117:e316\u20137.","journal-title":"Am J Gastroenterol"},{"key":"4434_CR17","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/ajg.2017.202","volume":"112","author":"T Greuter","year":"2017","unstructured":"Greuter T, Bussmann C, Safroneeva E, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 2017;112:1527\u201335.","journal-title":"Am J Gastroenterol"},{"key":"4434_CR18","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","volume":"72","author":"ES Dellon","year":"2023","unstructured":"Dellon ES, Peterson KA, Mitlyng BL, et al. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Gut. 2023;72:1828\u201337.","journal-title":"Gut"},{"key":"4434_CR19","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","volume":"390","author":"M Chehade","year":"2024","unstructured":"Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N Engl J Med. 2024;390:2239\u201351.","journal-title":"N Engl J Med"},{"key":"4434_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387:2317\u201330.","journal-title":"N Engl J Med"},{"key":"4434_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1053\/j.gastro.2006.08.033","volume":"131","author":"MR Konikoff","year":"2006","unstructured":"Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006;131:1381\u201391.","journal-title":"Gastroenterology"},{"key":"4434_CR22","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.cgh.2022.02.013","volume":"20","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Lucendo AJ, Schlag C, et al. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial. Clin Gastroenterol Hepatol. 2022;20:2485-2494.e15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4434_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/apt.15670","volume":"51","author":"I Hirano","year":"2020","unstructured":"Hirano I, Safroneeva E, Roumet MC, et al. Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2020;51:750\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"4434_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","volume":"143","author":"ES Dellon","year":"2012","unstructured":"Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143:321\u20134.","journal-title":"Gastroenterology"},{"key":"4434_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","volume":"13","author":"SK Gupta","year":"2015","unstructured":"Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13:66\u201376.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4434_CR26","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","volume":"147","author":"BK Butz","year":"2014","unstructured":"Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147(2):324-33.e5.","journal-title":"Gastroenterology"},{"key":"4434_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/MCG.0000000000001356","volume":"55","author":"T Rokkas","year":"2021","unstructured":"Rokkas T, Niv Y, Malfertheiner P. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol. 2021;55:400\u201310.","journal-title":"J Clin Gastroenterol"},{"key":"4434_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/dote\/doaa087.63","volume":"33","author":"C Ma","year":"2020","unstructured":"Ma C, Feagan B, Claveau D, et al. Comparative efficacy of corticosteroids formulations for the management of eosinophilic oesophagitis: a systematic review and network meta analysis. Dis Esophagus. 2020;33:24\u20135.","journal-title":"Dis Esophagus"},{"key":"4434_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/apt.13537","volume":"43","author":"S Lipka","year":"2016","unstructured":"Lipka S, Kumar A, Miladinovic B, et al. Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43:663\u201373.","journal-title":"Aliment Pharmacol Ther"},{"key":"4434_CR30","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1136\/gutjnl-2023-329873","volume":"72","author":"P Visaggi","year":"2023","unstructured":"Visaggi P, Barberio B, Del Corso G, et al. Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut. 2023;72:2019\u201330.","journal-title":"Gut"},{"issue":"2","key":"4434_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/1744666X.2023.2274940","volume":"20","author":"S Massironi","year":"2024","unstructured":"Massironi S, Elvevi A, Panceri R, et al. Eosinophilic esophagitis: does age matter? Expert Rev Clin Immunol. 2024;20(2):211\u201323.","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"4434_CR32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jaci.2022.09.027","volume":"150","author":"ME Rothenberg","year":"2022","unstructured":"Rothenberg ME. Scientific journey to the first FDA-approved drug for eosinophilic esophagitis. J Allergy Clin Immunol. 2022;150(6):1325\u201332.","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"4434_CR33","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1056\/NEJMra1502863","volume":"373","author":"GT Furuta","year":"2015","unstructured":"Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373(17):1640\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"4434_CR34","first-page":"294","volume":"16","author":"C Beveridge","year":"2020","unstructured":"Beveridge C, Falk GW. Novel therapeutic approaches to eosinophilic esophagitis. Gastroenterol Hepatol (N Y). 2020;16(6):294\u2013301.","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04434-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04434-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:15:12Z","timestamp":1767032112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04434-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04434-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"type":"electronic","value":"1471-230X"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and informed consent are not required for this meta-analysis as it utilized previously published data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"877"}}